

## **Cynata Receives Notice of Acceptance from IP Australia for Novel Application of Cymerus™ MSCs**

**Melbourne, Australia; 9 January 2023:** Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, has today announced that a Notice of Acceptance has been received from IP Australia, the intellectual property office of the Australian Government, for a patent application covering its proprietary Cymerus™ mesenchymal stem cell (MSC) platform technology. The patent application entitled “Method for Treating Allergic Airways Disease (AAD)/Asthma” is wholly owned by Cynata and describes a novel method of use of Cynata’s proprietary Cymerus MSC products in treating diseases of the lungs and airways.

The Notice of Acceptance is sent to the applicant when IP Australia intends to issue a patent. The patent adds to the existing broad and comprehensive IP protection of the Cymerus platform and its unique ability to yield highly consistent MSCs at scale, from a single donation, to create therapeutic stem cell products.

**Dr Kilian Kelly, Cynata’s Chief Operating Officer, said:**

*“We are very pleased that this novel application of Cymerus MSCs has resulted in yet a further patent, particularly in the clinically challenging area of lung disease and more especially including asthma. This important achievement adds to our portfolio of wholly-Cynata owned patents and patent applications, providing further protection over our proprietary Cymerus technology. The novel method of treatment described in the patent specification and patent claims enhances our competitive position in the clinical application of our cell therapy products. This strengthens our intellectual property position around the Cymerus platform which enables the production of consistent, high-quality mesenchymal stem cells at scale. These important characteristics afford a major competitive advantage in the ongoing development of off-the-shelf therapeutic stem cell products to target a range of devastating diseases worldwide”.*

Cynata anticipates that the patent will be granted around mid-March 2023, with an expiration date of 31 August 2038.

-ENDS-

Authorised for release by Dr Ross Macdonald, Managing Director & CEO

**CONTACTS:** Dr Ross Macdonald, CEO, Cynata Therapeutics, +61 (0)412 119 343, [ross.macdonald@cynata.com](mailto:ross.macdonald@cynata.com)  
Lauren Nowak, Media Contact, +61 (0)400 434 299, [laurenmaree@live.com.au](mailto:laurenmaree@live.com.au)

### **About Cynata Therapeutics (ASX: CYP)**

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.



Cynata's lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Planning for a Phase 2 clinical trial in GvHD under a cleared US FDA IND is presently underway. Clinical trials of Cymerus products in osteoarthritis (Phase 3), respiratory failure and diabetic foot ulcers (DFU) are currently ongoing. In addition, Cynata has demonstrated utility of its Cymerus technology in preclinical models of numerous diseases, including the clinical targets mentioned above, as well as critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.

**Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.**